T cell receptor recognition of tumor-associated antigen peptides presented on MHC by plasmacytoid dendritic cells

T-cell receptor (TCR) recognition of tumor-associated antigen (TAA) peptides presented on Major Histocompatibility Complex (MHC) by plasmacytoid dendritic cells (pDCs) is a critical immunological process for inducing anti-tumor immunity [6, 12]. While pDCs are primarily recognized for their role in innate immunity through the production of Type I interferons, they also function as professional antigen-presenting cells (APCs) that can prime naive T cells and activate tumor-specific cytotoxic T lymphocytes (CTLs) [11, 13]. In the tumor microenvironment, pDCs are often found in a dysfunctional or tolerogenic state, contributing to immune evasion; however, therapeutic strategies such as pDC-based vaccines aim to exploit this interaction to stimulate a robust adaptive immune response [15, 16]. Drugs like PDC*lung01 and PDC*mel utilize a specialized pDC cell line loaded with tumor antigens to facilitate this TCR-pMHC interaction, thereby expanding the pool of tumor-reactive T cells in patients [8, 10]. Additionally, adjuvants like TLR7/9 agonists (e.g., Imiquimod, CpG ODN) can be used to mature pDCs, enhancing their capacity to present antigens and provide necessary costimulatory signals [17, 19]. Monitoring this interaction often involves measuring the frequency of antigen-specific T cells and the production of effector cytokines like IFN-gamma [7, 8]. Safety concerns associated with modulating this pathway include potential off-target autoimmunity and injection site reactions, though pDC-based therapies have generally shown a favorable safety profile in clinical trials [8, 10].

Other names

pDC-mediated antigen presentationPlasmacytoid dendritic cell vaccine mechanismTCR-pMHC interaction on pDCspDC-based tumor antigen presentation

The mechanism involves the presentation of tumor-associated antigen (TAA) peptides by Major Histocompatibility Complex (MHC) molecules on the surface of plasmacytoid dendritic cells (pDCs) to cognate T-cell receptors (TCRs) on T cells, leading to the activation, proliferation, and differentiation of tumor-specific cytotoxic and helper T cells [6, 11, 13].